JWH-250
This is an old revision of this page, as edited by C6541 (talk | contribs) at 17:56, 27 November 2012 (added Category:Designer drugs using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H25NO2 |
Molar mass | 335.439 g/mol g·mol−1 |
3D model (JSmol) | |
| |
NY (what is this?) (verify) |
JWH-250 or (1-pentyl-3-(2-methoxyphenylacetyl)indole) is an analgesic chemical from the phenylacetylindole family that acts as a cannabinoid agonist at both the CB1 and CB2 receptors, with a Ki of 11nM at CB1 and 33nM at CB2. Unlike many of the older JWH series compounds, this compound does not have a naphthalene ring, instead occupying this position with a 2'-methoxy-phenylacetyl group, making JWH-250 a representative member of a new class of cannabinoid ligands.[2] Other 2'-substituted analogues such as the methyl, chloro and bromo compounds are also active and somewhat more potent.[3][4]
History
JWH-250 was discovered by, and named after the researcher Dr. John W. Huffman. He created JWH-250 and a number of other compounds to research the structure and function of the endocannabinoid system of mammals. Samples of JWH-250 were first identified in May 2009 by the German Federal Criminal Police, as an ingredient in new generation "herbal smoking blends" that had been released since the banning of the original ingredients (C8)-CP 47,497 and JWH-018.[5]
References
- ^ Legal article in Latvian (www.likumi.lv)
- ^ Huffman, JW; et al. (2005). "1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles". Bioorganic & Medicinal Chemistry Letters. 15 (18): 4110–3. doi:10.1016/j.bmcl.2005.06.008. PMID 16005223.
{{cite journal}}
: Explicit use of et al. in:|first=
(help) - ^ Manera, C; Tuccinardi, T; Martinelli, A (2008). "Indoles and related compounds as cannabinoid ligands". Mini reviews in medicinal chemistry. 8 (4): 370–87. doi:10.2174/138955708783955935. PMID 18473928.
- ^ The Cannabinoid Receptors. Edited by Patricia H Reggio. Humana Press 2009. ISBN 978-1-58829-712-9
- ^ Understanding the ‘Spice’ phenomenon. EMCDDA, Lisbon, November 2009
Opioids |
| ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Paracetamol-type | |||||||||||||||||
NSAIDs |
| ||||||||||||||||
Cannabinoids | |||||||||||||||||
Ion channel modulators |
| ||||||||||||||||
Myorelaxants | |||||||||||||||||
Others | |||||||||||||||||
|
Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||
Allosteric CBRTooltip Cannabinoid receptor ligands | |||||||||||||||||||||||||||||||||||||||||
Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||
Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||
|
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
- CS1 errors: explicit use of et al.
- Drugs with non-standard legal status
- Articles with changed EBI identifier
- Chem-molar-mass both hardcoded and calculated
- Infobox-drug molecular-weight unexpected-character
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All stub articles